473416-33-0

Basic information

• Product Name: (5-Fluorobenzofuran-2-yl)boronic acid
• Synonyms: (5-Fluorobenzofuran-2-yl)boronic acid;5-fluorobenzofuran-2-boronic acid;Boronic acid, (5-fluoro-2-benzofuranyl)- (9CI)
• CAS NO: 473416-33-0
• Molecular Formula: C8H6BFO3
• Molecular Weight: 179.9408432
• Product Categories: Organic boronic acid
• Mol File: 473416-33-0.mol

Chemical Properties

• Boiling Point: 343.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 5.88±0.30(Predicted)
• CAS DataBase Reference: (5-Fluorobenzofuran-2-yl)boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Fluorobenzofuran-2-yl)boronic acid(473416-33-0)
• EPA Substance Registry System: (5-Fluorobenzofuran-2-yl)boronic acid(473416-33-0)

Safety Data

• Hazardous Substances Data: 473416-33-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-Fluorobenzofuran-2-yl)boronic acid is used as a reagent for the preparation of heterocyclic compounds that can inhibit the activity of PASK (Proline-Alanine-Serine-Proline Kinase). This inhibition is particularly useful for the treatment of diseases like diabetes mellitus, as it can help regulate cellular processes and improve overall metabolic health. By targeting PASK, these heterocyclic compounds have the potential to offer novel therapeutic approaches for managing diabetes and its associated complications.

Upstream product

• 24410-59-1 5-Fluoro[b]benzofuran 
• 5419-55-6 Triisopropyl borate 
• 7732-18-5 water 
• 371-41-5 4-Fluorophenol 
• 59769-37-8 2-(4-Fluorophenoxy)-acetaldehyde Diethyl Acetal 
• 150-46-9 triethyl borate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

NOVEL 1H-INDAZOLE COMPOUND

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by -CO-NH- or -NH-CO-, etc.; and Y is a C3-C8 cycloalkyl group, a C6-C14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.